Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00771134 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression
A Phase 2 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00771134 is a Phase 2 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 105 participants.
The verdict
NCT00771134, a Phase 2 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of Lu AA39959 in the treatment of depression in patients with bipolar disorder.
Interventions
- DRUG Placebo
- DRUG Quetiapine
- DRUG Lu AA39959
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00771134
The ClinicalTrials.gov registry entry for NCT00771134 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00771134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00771134 about?
NCT00771134 is a clinical study titled "Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression". This study will evaluate the efficacy and safety of Lu AA39959 in the treatment of depression in patients with bipolar disorder.
What is the current status of trial NCT00771134?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2008-12. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00771134?
The interventions under investigation include: Placebo (DRUG), Quetiapine (DRUG), Lu AA39959 (DRUG).
Who is sponsoring clinical trial NCT00771134?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.